← Back to COAGPortrait, one to two pages. Turn on “background graphics” in the print dialog to keep the table rules.
SPZCOHemab Therapeutics Holdings, Inc. · COAGData at close 2026-07-29
Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 2114044 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
COAG close: $34.0 on 2026-05-01 to $44.8 on 2026-07-29.
Daily closing price, split-adjusted to the current basis; 0.2y shown of 51 bars on file. Sampled to 51 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
At a glance
Short interest3.6% of sh out
Days to cover5.3d
Next report (est.)2026-08-20
Short interest is FINRA semi-monthly, settlement 2026-07-15.
Key fundamentals
No standardized fundamentals available.
Trailing returns
No return windows available for COAG.
Risk
Ann. volatility (1Y)112.3%
Ann. volatility (3Y)112.3%
Sharpe (1Y)1.81
Sharpe (3Y)1.81
Max drawdown (1Y)−26.5%
Max drawdown (3Y)−26.5%
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
Top institutional holders13F 2026-Q1
No 13F holders on file for COAG.
Latest reported quarterslast report 2026-05-21
No reported quarters on file for COAG.
Basis & disclosures
End-of-day only. Every price on this sheet is a stored CLOSE — the last one is 2026-07-29. Nothing here is live, intraday or delayed-real-time, and the sheet does not update after it is printed.
Nothing is imputed. A figure that is not in the underlying filing or feed renders as “—”. We never fill a gap with an estimate, a peer median or a carried-forward value.
Mixed as-of dates by design. Prices are at the last close; fundamentals are at the latest reported fiscal period; 13F ownership is at the latest filed quarter (45+ days in arrears); short interest is the latest FINRA settlement. Each block states its own basis above.
Not investment advice. Model fair values, reverse-DCF grades and confidence labels are the output of published, disclosed methods on public filings — they are analysis, not a recommendation, a price target or a solicitation.
Fundamentals and ownership derive from SEC EDGAR (and equivalent foreign registers); prices from a licensed end-of-day vendor, shown under a neutral source label. Full methodology at spzco.com/methodology.
